<DOC>
	<DOCNO>NCT00684138</DOCNO>
	<brief_summary>Randomized , parallel group , subject mask , multi-center six ( 6 ) month follow-up study compare ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power IOL Model SN6AD1 implant eye ACRYSOF® ReSTOR® Aspheric +4.0 D Add Power IOL Model SN6AD3 implant eye .</brief_summary>
	<brief_title>ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens ( IOL )</brief_title>
	<detailed_description />
	<mesh_term>Cataract</mesh_term>
	<criteria>Inclusion : Adults , 21 year age old time surgery , either gender race , diagnose bilateral cataract Calculated lens power within available range Willing able complete require postoperative visit Planned cataract removal phacoemulsification and/or liquifacture Potential postoperative visual acuity 0.2 logMAR well study eye Preoperative astigmatism 1.0 Diopter ( D ) less , measure keratometry study eye Clear intraocular medium cataract study eye Able comprehend sign statement inform consent Preoperative Best Corrected Distance Visual Acuity ( BCDVA ) worse 0.2 logMAR , BCDVA equal well 0.2 logMAR , BCDVA Brightness Acuity Tester ( BAT ) `` Medium '' set must worse 0.2 logMAR Exclusion : Significant irregular corneal aberration demonstrate corneal topography Subjects diagnose degenerative visual disorder ( e.g. , macular degeneration retinal disorder ) predict cause future acuity loss level bad 0.2 logMAR Subjects may reasonably expect require laser treatment time Previous corneal refractive surgery Amblyopia Clinically severe corneal dystrophy ( e.g. , epithelial , stromal , endothelial dystrophy ) Diabetic retinopathy Extremely shallow anterior chamber , due swell cataract Microphthalmos Previous retinal detachment Previous corneal transplant Recurrent severe anterior posterior segment inflammation unknown etiology Rubella traumatic cataract Iris neovascularization Glaucoma ( uncontrolled control medication ) Aniridia Optic nerve atrophy Pregnancy Current previous usage alpha1selective adrenoceptor block agent antagonist alpha 1A adrenoceptor ( e.g.Flomax® ( tamsulosin HCL ) , Hytrin® , Cardura® ) Any subject currently participate another investigational drug device study may confound result investigation</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>cataract</keyword>
	<keyword>cataract surgery</keyword>
	<keyword>IOL</keyword>
	<keyword>intraocular lens</keyword>
	<keyword>ReSTOR</keyword>
	<keyword>Replacement cataract</keyword>
</DOC>